ARGX Shares Surge 1.82% on $400M Volume, Jumps to 279th Most Traded Amid Canada VYVGART Approval

Market Snapshot

On November 14, 2025, argenx (ARGX) closed with a 1.82% increase in share price, reflecting positive momentum in its trading activity. The stock recorded a trading volume of $0.40 billion, marking a 40.56% surge compared to the previous day’s volume. This elevated liquidity positioned argenx as the 279th most actively traded stock of the day, indicating heightened investor interest. The volume spike and upward price movement suggest a potential catalyst driving short-term demand, possibly linked to recent regulatory developments or market sentiment shifts.

Key Drivers

The recent Health Canada approval of VYVGART SC for treating chronic inflammatory demyelinating polyneuropathy (CIDP) represents a pivotal milestone for argenx. As the first FcRn blocker approved in Canada for this indication, VYVGART SC introduces a once-weekly subcutaneous self-administration option, offering greater patient convenience and potentially reducing reliance on human-derived blood products. This regulatory win builds on the April 2025 FDA approval of VYVGART Hytrulo for self-administration in CIDP, reinforcing argenx’s strategy to expand treatment accessibility and diversify its revenue streams. The Canadian approval demonstrates the company’s ability to execute its global regulatory and commercialization plan, providing a tangible catalyst for long-term growth.

Analyst sentiment and financial forecasts further underscore argenx’s growth trajectory. The company’s projected revenue of $6.9 billion and earnings of $2.6 billion by 2028—driven by a 30.6% annual revenue growth rate—align with its expanding pipeline and market penetration. Recent analyst updates, including TD Cowen’s raised price target to $1,146 and Piper Sandler’s $930 target, reflect confidence in VYVGART’s commercial potential and the broader therapeutic pipeline. These valuations, however, highlight divergent views among investors, with community fair value estimates ranging from €530.28 to €2,130.83 per share. Such variability underscores the dual influence of optimism around market expansion and concerns over competitive pressures from emerging therapies in the CIDP and neuromuscular disease spaces.

The company’s recent financial performance also bolsters its growth narrative. In Q2 2025, argenx reported earnings of $6.32 per share, doubling expectations, with revenue reaching $1.74 billion—98.56% above forecasts. This outperformance, driven by Vyvgart’s 97% year-over-year sales growth, highlights the product’s strong market adoption. A robust cash balance of $3.9 billion and a 3.57/5 financial health score further reinforce investor confidence in argenx’s ability to fund R&D and expand its global footprint. With six Phase 3 and six Phase 2 trials expected to yield data in the next 18 months, the company is positioned to generate momentum across its pipeline, including empasiprubart and ARGX-119, which target additional autoimmune and neuromuscular conditions.

Despite these positives, competitive dynamics remain a critical risk factor. Emerging therapies from rivals could erode market share, particularly as other companies advance treatments for CIDP and related diseases. Additionally, argenx’s heavy reliance on VYVGART for revenue—accounting for a significant portion of its current earnings—poses concentration risks. While the recent Health Canada approval and global regulatory strategy aim to mitigate these challenges, the company must continue to innovate and secure additional indications to sustain long-term growth. Analysts emphasize the importance of monitoring clinical trial outcomes and payer reimbursement trends, which will shape the commercial viability of argenx’s pipeline.

In summary, argenx’s recent regulatory approvals, strong financial performance, and analyst optimism position it for sustained growth. However, the biotech sector’s inherent volatility and competitive pressures necessitate a balanced view of its prospects. Investors will likely remain focused on the execution of its “Vision 2030” strategy, including global expansion and pipeline diversification, as key determinants of long-term value.